Upregulated Claudin-18.2 Is a Poor Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy.

IF 1.8 3区医学 Q3 ONCOLOGY

Oncology Pub Date : 2025-07-04 DOI:10.1159/000547239

Chia-Lin Chou, Han-Ping Hsu, Wan-Shan Li, Sung-Wei Lee, Ching-Chieh Yang, Yu-Feng Tian, Cheng-Yi Lin, Hung-Chang Wu, Yow-Ling Shiue, Yu-Hsuan Kuo

{"title":"Upregulated Claudin-18.2 Is a Poor Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy.","authors":"Chia-Lin Chou, Han-Ping Hsu, Wan-Shan Li, Sung-Wei Lee, Ching-Chieh Yang, Yu-Feng Tian, Cheng-Yi Lin, Hung-Chang Wu, Yow-Ling Shiue, Yu-Hsuan Kuo","doi":"10.1159/000547239","DOIUrl":null,"url":null,"abstract":"Introduction: Claudins are essential for tight junctions, maintaining cell adhesion, regulating intercellular molecule movement, and preserving cellular polarity. Altered claudin expression can lead to dysfunctions, potentially contributing to oncogenesis in epithelial cancers. The role of CLDN18.2 in rectal cancer is not well understood.Methods: We analyzed tissue samples from 343 rectal cancer patients who underwent concurrent chemoradiotherapy (CCRT) followed by proctectomy.Results: Upregulated CLDN18.2 expression was associated with older age (p = 0.016), higher pre-CCRT tumor N stage (p = 0.014), higher post-CCRT tumor T stage (p = 0.005), more vascular invasion (p = 0.008), and worse tumor regression (p < 0.001). Univariate analysis showed high CLDN18.2 expression correlated with worse disease-free survival (p < 0.0001), local recurrence-free survival (p < 0.0001), and metastasis-free survival (p < 0.0001). Multivariate analysis indicated high CLDN18.2 expression was associated with inferior disease-specific survival (p < 0.001) and metastasis-free survival (p < 0.001).Conclusion: Elevated CLDN18.2 expression is associated with adverse clinical outcomes and pathological features, yet suggests a more unfavorable treatment response in rectal cancer patients undergoing CCRT, indicating its potential as a biomarker.","PeriodicalId":19497,"journal":{"name":"Oncology","volume":" ","pages":"1-18"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547239","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Claudins are essential for tight junctions, maintaining cell adhesion, regulating intercellular molecule movement, and preserving cellular polarity. Altered claudin expression can lead to dysfunctions, potentially contributing to oncogenesis in epithelial cancers. The role of CLDN18.2 in rectal cancer is not well understood.

Methods: We analyzed tissue samples from 343 rectal cancer patients who underwent concurrent chemoradiotherapy (CCRT) followed by proctectomy.

Results: Upregulated CLDN18.2 expression was associated with older age (p = 0.016), higher pre-CCRT tumor N stage (p = 0.014), higher post-CCRT tumor T stage (p = 0.005), more vascular invasion (p = 0.008), and worse tumor regression (p < 0.001). Univariate analysis showed high CLDN18.2 expression correlated with worse disease-free survival (p < 0.0001), local recurrence-free survival (p < 0.0001), and metastasis-free survival (p < 0.0001). Multivariate analysis indicated high CLDN18.2 expression was associated with inferior disease-specific survival (p < 0.001) and metastasis-free survival (p < 0.001).

Conclusion: Elevated CLDN18.2 expression is associated with adverse clinical outcomes and pathological features, yet suggests a more unfavorable treatment response in rectal cancer patients undergoing CCRT, indicating its potential as a biomarker.

查看原文本刊更多论文

Claudin-18.2上调是直肠癌患者术前同步放化疗的不良预后指标

claudin是紧密连接、维持细胞粘附、调节细胞间分子运动和保持细胞极性所必需的。claudin表达的改变可导致功能障碍，潜在地促进上皮癌的发生。CLDN18.2在直肠癌中的作用尚不清楚。方法：我们分析了343例接受同步放化疗（CCRT）和直肠切除术的直肠癌患者的组织样本。结果：CLDN18.2表达上调与年龄较大（p = 0.016）、ccrt前肿瘤N分期较高（p = 0.014）、ccrt后肿瘤T分期较高（p = 0.005）、血管侵犯较多（p = 0.008）、肿瘤消退较差（p < 0.001）相关。单因素分析显示，CLDN18.2高表达与较差的无病生存期（p < 0.0001）、局部无复发生存期（p < 0.0001）和无转移生存期（p < 0.0001）相关。多因素分析显示，高表达的CLDN18.2与较差的疾病特异性生存（p < 0.001）和无转移生存（p < 0.001）相关。结论：升高的CLDN18.2表达与不良的临床结局和病理特征相关，但在接受CCRT的直肠癌患者中表明更不利的治疗反应，表明其作为生物标志物的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncology 医学-肿瘤学

CiteScore

6.00

自引率

2.90%

发文量

审稿时长

6-12 weeks

期刊介绍： Although laboratory and clinical cancer research need to be closely linked, observations at the basic level often remain removed from medical applications. This journal works to accelerate the translation of experimental results into the clinic, and back again into the laboratory for further investigation. The fundamental purpose of this effort is to advance clinically-relevant knowledge of cancer, and improve the outcome of prevention, diagnosis and treatment of malignant disease. The journal publishes significant clinical studies from cancer programs around the world, along with important translational laboratory findings, mini-reviews (invited and submitted) and in-depth discussions of evolving and controversial topics in the oncology arena. A unique feature of the journal is a new section which focuses on rapid peer-review and subsequent publication of short reports of phase 1 and phase 2 clinical cancer trials, with a goal of insuring that high-quality clinical cancer research quickly enters the public domain, regardless of the trial’s ultimate conclusions regarding efficacy or toxicity.